Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical Neuroradiology
Erschienen in: Clinical Neuroradiology 2/2015

01.10.2015 | Review Article

Advanced MR Imaging in Neuro-oncology

verfasst von: A. Radbruch, M. Bendszus

Erschienen in: Clinical Neuroradiology | Sonderheft 2/2015

Einloggen, um Zugang zu erhalten

Abstract

The value of magnetic resonance (MR) imaging for the clinical management of brain tumour patients has greatly increased in recent years through the introduction of functional MR sequences. Previously, MR imaging for brain tumours relied for the most part on contrast-enhanced T1-weighted MR sequences but today with the help of advanced functional MR sequences, the pathophysiological aspects of tumour growth can be directly visualised and investigated. This article will present the pathophysiological background of the MR sequences relevant to neuro-oncological imaging as well as potential clinical applications. Ultimately, we take a look at possible future developments for ultra-high-field MR imaging.
Literatur
1.
Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF. Pros and cons of current brain tumor imaging. Neuro Oncol. 2014;16 Suppl 7:2–11.CrossRef
2.
Niendorf HP, Laniado M, Semmler W, Schörner W, Felix R. Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors. AJNR Am J Neuroradiol. 1987;8(5):803–15.PubMed
3.
Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer G, Wick W, Bendszus M, Radbruch A. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology. 2014;82(19):1684–92.CrossRefPubMed
4.
Bähr O, Harter PN, Weise LM, You SJ, Mittelbronn M, Ronellenfitsch MW, Rieger J, Steinbach JP, Hattingen E. Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology. 2014;83(3):227–34.CrossRefPubMed
5.
Bähr O, Hattingen E, Rieger J, Steinbach JP. Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma. Neuro Oncol. 2011;13(9):1020–9.CrossRefPubMedCentralPubMed
6.
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72.CrossRefPubMed
7.
Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277–80.PubMed
8.
Radbruch A, Lutz K, Wiestler B, Bäumer P, Heiland S, Wick W, Bendszus M. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol. 2012;14(2):222–9.CrossRefPubMedCentralPubMed
9.
Reichenbach JR, Haacke EM. High-resolution BOLD venographic imaging: a window into brain function. NMR Biomed. 2001;14(7–8):453–67.CrossRefPubMed
10.
Reichenbach JR, Venkatesan R, Schillinger DJ, Kido DK, Haacke EM. Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. Radiology. 1997;204(1):272–7.CrossRefPubMed
11.
Kim HS, Jahng GH, Ryu CW, Kim SY. Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study. AJNR Am J Neuroradiol. 2009;30(8):1574–9.CrossRefPubMed
12.
Park MJ, Kim HS, Jahng GH, Ryu CW, Park SM, Kim SY. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol. 2009;30(7):1402–8.CrossRefPubMed
13.
Deistung A, Schweser F, Wiestler B, Abello M, Roethke M, Sahm F, Wick W, Nagel AM, Heiland S, Schlemmer HP, Bendszus M, Reichenbach JR, Radbruch A. Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma. PLoS One. 2013;8(3):e57924.CrossRefPubMedCentralPubMed
14.
Kickingereder P, Wiestler B, Sahm F, Heiland S, Roethke M, Schlemmer HP, Wick W, Bendszus M, Radbruch A. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. Radiology. 2014;272(3):843–50.CrossRefPubMed
15.
Radbruch A, Graf M, Kramp L, Wiestler B, Floca R, Bäumer P, Roethke M, Stieltjes B, Schlemmer HP, Heiland S, Bendszus M. Differentiation of brain metastases by percentagewise quantification of intratumoral-susceptibility-signals at 3 T. Eur J Radiol. 2012;81(12):4064–8.CrossRefPubMed
16.
Mohammed W, Xunning H, Haibin S, Jingzhi M. Clinical applications of susceptibility-weighted imaging in detecting and grading intracranial gliomas: a review. Cancer Imaging. 2013;13:186–95.CrossRefPubMedCentralPubMed
17.
Lupo JM, Essock-Burns E, Molinaro AM, Cha S, Chang SM, Butowski N, Nelson SJ. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. Neuro Oncol. 2013;15(4):480–9.CrossRefPubMedCentralPubMed
18.
Schweser F, Deistung A, Lehr BW, Reichenbach JR. Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys. 2010;37(10):5165–78.CrossRefPubMed
19.
Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, Johnson G. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004;25(5):746–55.PubMed
20.
Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC, Golfinos JG, Zagzag D, Johnson G. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247(2):490–8.CrossRefPubMedCentralPubMed
21.
Vidiri A, Pace A, Fabi A, Maschio M, Latagliata GM, Anelli V, Piludu F, Carapella CM, Giovinazzo G, Marzi S. Early perfusion changes in patients with recurrent high-grade brain tumor treated with bevacizumab: preliminary results by a quantitative evaluation. J Exp Clin Cancer Res. 2012;31:33.CrossRefPubMedCentralPubMed
22.
Kickingereder P, Wiestler B, Burth S, Wick A, Nowosielski M, Heiland S, Schlemmer HP, Wick W, Bendszus M, Radbruch A. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncol. 2015;17:1139–47.CrossRefPubMed
23.
Tsien C, Galbán CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, Junck L, Meyer CR, Rehemtulla A, Lawrence T, Ross BD. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol. 2010;28(13):2293–9.CrossRefPubMedCentralPubMed
24.
Radbruch A, Fladt J, Kickingereder P, Wiestler B, Nowosielski M, Bäumer P, Schlemmer HP, Wick A, Heiland S, Wick W, Bendszus M. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro Oncol. 2015;17(1):151–9.CrossRefPubMed
25.
26.
Heiland S, Wick W, Bendszus M. Perfusion magnetic resonance imaging for parametric response maps in tumors: is it really that easy? J Clin Oncol. 2010. 28(29):e591. (author reply e592).CrossRefPubMed
27.
Radbruch A, Bendszus M, Wick W, Heiland S. Comment to: Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma: pitfalls in perfusion MRI in brain tumors: Tsien C, Galban CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, Junck L, Meyer CR, Rehemtulla A, Lawrence T, Ross BD. J Clin Oncol. 2010;28:2293–9. Clin Neuroradiol. 2010;20(3):183–4.CrossRefPubMed
28.
Blasel S, Jurcoane A, Franz K, Morawe G, Pellikan S, Hattingen E. Elevated peritumoural rCBV values as a mean to differentiate metastases from high-grade gliomas. Acta Neurochir (Wien). 2010;152(11):1893–9.CrossRef
29.
Stecco A, Pisani C, Quarta R, Brambilla M, Masini L, Beldì D, Zizzari S, Fossaceca R, Krengli M, Carriero A. DTI and PWI analysis of peri-enhancing tumoral brain tissue in patients treated for glioblastoma. J Neurooncol. 2011;102(2):261–71.CrossRefPubMed
30.
Hakyemez B, Erdogan C, Gokalp G, Dusak A, Parlak M. Solitary metastases and high-grade gliomas: radiological differentiation by morphometric analysis and perfusion-weighted MRI. Clin Radiol. 2010;65(1):15–20.CrossRefPubMed
31.
Xu XX, Li B, Yang HF, Du Y, Li Y, Wang WX, Zheng HJ, Gong QY. Can diffusion-weighted imaging be used to differentiate brain abscess from other ring-enhancing brain lesions? A meta-analysis. Clin Radiol. 2014;69(9):909–15.CrossRefPubMed
32.
Gupta RK, Cloughesy TF, Sinha U, Garakian J, Lazareff J, Rubino G, Rubino L, Becker DP, Vinters HV, Alger JR. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol. 2000;50(3):215–26.CrossRefPubMed
33.
Sugahara T KY, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okuda T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9(1):53–60.CrossRefPubMed
34.
Gupta R, Sinha U, Cloughesy TF, Alger JR. Inverse correlation between choline magnetic resonance spectroscopy signal intensity and the apparent diffusion coefficient in human glioma. Magn Reson Med. 1999;41:2–7.CrossRefPubMed
35.
Lutz K, Wiestler B, Graf M, Bäumer P, Floca R, Schlemmer HP, Heiland S, Wick W, Bendszus M, Radbruch A. Infiltrative patterns of glioblastoma: Identification of tumor progress using apparent diffusion coefficient histograms. J Magn Reson Imaging. 2014;39(5):1096–103.CrossRefPubMed
36.
Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182–9.CrossRefPubMed
37.
Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, Xue X, Goldin J, Brown MS, Nghiemphu PL, Tran A, Cloughesy TF. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011;32(5):882–9.CrossRefPubMed
38.
Provenzale JM, McGraw P, Mhatre P, Guo AC, Delong D. Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. Radiology. 2004;232(2):451–60.CrossRefPubMed
39.
Deng Z, Yan Y, Zhong D, Yang G, Tang W, Lü F, Xie B, Liu B. Quantitative analysis of glioma cell invasion by diffusion tensor imaging. J Clin Neurosci. 2010;17(12):1530–6.CrossRefPubMed
40.
Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas. Radiology. 2012;264(3):834–43.CrossRefPubMed
41.
Radbruch A, Schlemmer HP. Application of ultrahigh-field MRI in neuro-oncology. Radiologe. 2013;53(5):411–4.CrossRefPubMed
42.
Balchandani P, Naidich TP. Ultra-high-field MR neuroimaging. AJNR Am J Neuroradiol. 2015;36:1204–15.CrossRefPubMed
43.
Radbruch A, Eidel O, Wiestler B, Paech D, Burth S, Kickingereder P, Nowosielski M, Bäumer P, Wick W, Schlemmer HP, Bendszus M, Ladd M, Nagel AM, Heiland S. Quantification of tumor vessels in glioblastoma patients using time-of-flight angiography at 7 T: a feasibility study. PLoS One. 2014;9:e110727.
44.
Nagel AM, Bock M, Hartmann C, Gerigk L, Neumann JO, Weber MA, Bendszus M, Radbruch A, Wick W, Schlemmer HP, Semmler W, Biller A. The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors. Invest Radiol. 2011;46(9):539–47.CrossRefPubMed
45.
Nagel AM, Lehmann-Horn F, Weber MA, Jurkat-Rott K, Wolf MB, Radbruch A, Umathum R, Semmler W. In vivo 35Cl MR imaging in humans: a feasibility study. Radiology. 2014;271(2):585–95.CrossRefPubMed
46.
Hoffmann SH, Radbruch A, Bock M, Semmler W, Nagel AM. Direct (17)O MRI with partial volume correction: first experiences in a glioblastoma patient. MAGMA. 2014;27(6):579–87.CrossRefPubMed
47.
Paech D, Zaiss M, Meissner JE, Windschuh J, Wiestler B, Bachert P, Neumann JO, Kickingereder P, Schlemmer HP, Wick W, Nagel AM, Heiland S, Ladd ME, Bendszus M, Radbruch A. Nuclear Overhauser enhancement mediated chemical exchange saturation transfer imaging at 7 T in glioblastoma patients. PLoS One. 2014;9(8):e104181.CrossRefPubMedCentralPubMed
48.
Windschuh J, Zaiss M, Meissner JE, Paech D, Radbruch A, Ladd ME, Bachert P. Correction of B1-inhomogeneities for relaxation-compensated CEST imaging at 7 T. NMR Biomed. 2015;28(5):529–37.CrossRefPubMed
49.
Zaiss M, Windschuh J, Paech D, Meissner JE, Burth S, Schmitt B, Kickingereder P, Wiestler B, Wick W, Bendszus M, Schlemmer HP, Ladd ME, Bachert P, Radbruch A. Relaxation-compensated CEST-MRI of the human brain at 7 T: unbiased insight into NOE and amide signal changes in human glioblastoma. Neuroimage. 2015;112:180–8.CrossRefPubMed
50.
Zaiss M, Kunz P, Goerke S, Radbruch A, Bachert P. MR imaging of protein folding in vitro employing nuclear-Overhauser-mediated saturation transfer. NMR Biomed. 2013;26(12):1815–22.CrossRefPubMed
Metadaten
Titel
Advanced MR Imaging in Neuro-oncology
verfasst von
A. Radbruch
M. Bendszus
Publikationsdatum
01.10.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Neuroradiology / Ausgabe Sonderheft 2/2015
Print ISSN: 1869-1439
Elektronische ISSN: 1869-1447
DOI
https://doi.org/10.1007/s00062-015-0439-2

Weitere Artikel der Sonderheft 2/2015

Clinical Neuroradiology 2/2015 Zur Ausgabe

Kurzübersicht

Anfänge und Entwicklungen der endoluminalen neurovaskulären Therapie

Review Article

Perspectives of Ultra-High-Field MRI in Neuroradiology

Kurzübersicht

Analyse zur Internetpräsenz der Deutschen Gesellschaft für Neuroradiologie

Kurzübersicht

Der lange Weg zu einer wirksamen Behandlung der akuten zerebralen Ischämie

Review Article

Flat-Panel Computed Tomography (DYNA-CT) in Neuroradiology. From High-Resolution Imaging of Implants to One-Stop-Shopping for Acute Stroke

Review Article

Imaging Neurodegeneration: Steps Toward Brain Network-Based Pathophysiology and Its Potential for Multi-modal Imaging Diagnostics

Neu im Fachgebiet Radiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise